Doxorubicin by Shanghai Affinity Biopharmaceutical for Lung Adenocarcinoma: Likelihood of Approval

Doxorubicin is under clinical development by Shanghai Affinity Biopharmaceutical and currently in Phase III for Lung Adenocarcinoma.

Source link
#Doxorubicin #Shanghai #Affinity #Biopharmaceutical #Lung #Adenocarcinoma #Likelihood #Approval